Drug-Induced Liver Injury From Cancer Therapies

Nov 11 2023
Republic Ballroom - Sheraton Boston Hotel
11:00 AM - 12:30 PM EST

Speakers

Jay H. Hoofnagle

NIDDK, NIH, Liver Diseases Branch

Lucia Anne Possamai

Imperial College of London

Kim L.R. Brouwer

University of North Carolina, Chapel Hill

Michael Li

University of California, San Francisco

Description

This session is focused on mechanistic, translational and clinical aspects of drug-induced liver injury (DILI). Speakers will share an update on the traditional chemotherapy DILI and discuss liver-related side effects of novel cancer chemotherapeutics, such as immune checkpoint inhibitors and how to diagnose and treat these injuries. The session is organized by the Hepatotoxicity Special Interest Group.

Objectives

  • Determine the clinical presentation of hepatotoxicity from cancer chemotherapy
  • Know the most common causes of drug-induced liver injury in cancer patients and what is required to make the diagnosis
  • Describe the clinical management and latest data on the treatment of patients with immune checkpoint inhibitor hepatotoxicity